US 12,285,422 B2
Uses of piperidinyl-indole derivatives
Jorg Eder, Rheinfelden (DE); Richard Alexander Harrison, Shropshire (GB); Boerje Haraldsson, Riehen (CH); and Anna Svenja Shchubart Wellensiek, Basel (CH)
Assigned to Novartis AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Jan. 31, 2022, as Appl. No. 17/589,281.
Application 17/589,281 is a continuation of application No. 16/642,905, abandoned, previously published as PCT/IB2018/056618, filed on Aug. 30, 2018.
Claims priority of application No. 17188870 (EP), filed on Aug. 31, 2017.
Prior Publication US 2022/0152011 A1, May 19, 2022
Int. Cl. A61K 31/454 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/454 (2013.01) [A61P 13/12 (2018.01)] 15 Claims
 
1. A method of treating C3 glomerulopathy (C3G), in a patient suffering therefrom, comprising the step of administering at a dose of 200 mg given twice per day of a compound of formula (I) or a pharmaceutically acceptable salt thereof to the patient, wherein

OG Complex Work Unit Chemistry
R is hydrogen, C1-C4alkyl, or C1-C6alkoxy;
R1 is C1-C6alkoxy;
R2 is C1-C6alkyl;
R3 is C1-C6alkoxy; C1-C6alkyl; or hydroxyl;
R4 is phenyl, optionally substituted by —C(O)R8, and
R8 is hydroxy, C1-C4alkoxy, or amino.